Planet Microcap Podcast | Microcap Investing Strategies

My guest on the show today is Rene Goehrum, President, CEO and Chairman of BioSyent (TSX-V: RX). BioSyent is a specialty pharmaceutical company focused on commercializing products that the company says provides a distinguishable benefit to patients and their healthcare providers and, according to their website, is known for their ability to effectively and efficiently introduce new products to the Canadian market. BioSyent is, as the company states on their website, actively sought out as the Canadian market partner of choice by brand innovators with niche or specialty products looking for a trusted partner. The first time we interviewed Rene was back in June 2013. At the beginning of June 2013, the stock was trading around $1.30, and as of recording of this introduction, the morning of September 15, 2023, the stock closed at $7.85. Furthermore, as of Q2 2023, the company has reported 52 consecutive profitable quarters, according to their Q2 2023 results presentation. Many of you listening know the BioSyent s